Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

4306studies shown

Showing 1,741-1,752 of 4,306

CompletedEUCTR 2010-018408-96

A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine using Olanzapine as an Active Control in Subjects Diagnosed with Schizophrenia who Completed Protocol...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Bulgaria
Sponsor: Schering-Plough Research Institute, a Division of Schering
Condition: Schizophrenia

View study

CompletedEUCTR 2009-017852-28

A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 versus Placebo in Patients with DSM-IVTR Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Germany
Sponsor: Eli Lilly and Company
Condition: Schizophrenia

View study

CompletedEUCTR 2009-012568-14

A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Monotherapy in Adult Patients with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Bulgaria, Slovakia
Sponsor: Otsuka Pharmaceutical Development & Commercialization
Condition: Schizophrenia

View study

TerminatedEUCTR 2011-004845-42

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 165)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: United Kingdom, Czechia, Poland
Sponsor: Amgen Inc.
Condition: Schizophrenia

View study

CompletedEUCTR 2011-004844-23

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 299)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Italy

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Italy, Spain
Sponsor: Amgen Inc.
Condition: Schizophrenia

View study

CompletedEUCTR 2016-003436-20

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Bulgaria, Czechia, Hungary, ...
Sponsor: ACADIA Pharmaceuticals Inc.
Condition: Schizophrenia

View study

CompletedEUCTR 2013-002193-45

A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALK 3831, in Adults with Schizophrenia Treated with Olanzapine

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Bulgaria, Czechia
Sponsor: Alkermes Inc.
Condition: Schizophrenia

View study

CompletedEUCTR 2020-000094-24

A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Bulgaria, Croatia, Latvia, ...
Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Condition: Schizophrenia

View study

CompletedEUCTR 2007-003820-40

A Phase 3 Randomized, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Lithuania

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Lithuania
Sponsor: Dainippon Sumitomo Pharma America, Inc.
Condition: Schizophrenia

View study

CompletedEUCTR 2007-003819-31

A Phase 3 Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: France
Sponsor: Dainippon Sumitomo Pharma America, Inc
Condition: Schizophrenia

View study

CompletedEUCTR 2015-003373-15

A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects with Acute Exacerbation of Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Bulgaria, Hungary, Slovakia
Sponsor: Alkermes Inc
Condition: Schizophrenia

View study

CompletedEUCTR 2015-003880-13

A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Bulgaria, Hungary, Slovakia
Sponsor: Alkermes Inc
Condition: Schizophrenia

View study

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.